51 results
8-K
EX-99.1
ARQT
Arcutis Biotherapeutics Inc
10 Apr 24
Departure of Directors or Certain Officers
4:15pm
and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including two FDA approved
8-K
EX-99.1
ARQT
Arcutis Biotherapeutics Inc
27 Feb 24
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:44am
the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent
8-K
EX-99.1
3i6tsx1 i9b3ks2
3 Nov 23
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
7:32am
8-K
EX-99.1
x6gyx7rk1bhgqf
27 Sep 23
Departure of Directors or Certain Officers
4:30pm
8-K
EX-99.1
b3b4shf29ohrao9xzovq
18 Aug 23
Departure of Directors or Certain Officers
4:32pm
8-K
EX-99.1
wg9fn2jvo1kaaylgv
8 Aug 23
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
4:04pm
8-K
EX-99.1
5h554xecyfdf0zjvop2
24 May 23
Arcutis Announces Leadership Transition
5:03pm
8-K
EX-99.1
u8uk vvuv2pz93
9 May 23
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
4:03pm
8-K
EX-99.1
b9f7k3lkiw
8 Nov 22
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
j8yp9 b9vnnr2t4r1u
7 Sep 22
Entry into a Material Definitive Agreement
5:04pm